Altimmune Draws $10 Million Under Hercules Capital Loan Agreement
Bitget2026/10/29 11:20- Altimmune drew $10 million in Tranche Three on October 27, 2026, under a $125 million loan agreement with Hercules Capital and other lenders.
- Meeting clinical and financial milestones extended the interest-only period and amortization date to June 1, 2028.
- The minimum cash covenant now requires qualified cash equal to at least 60% of outstanding Term Loan Advances principal.
- A 1% tranche facility charge was deducted from funding; the end-of-term charge remains 6.25% of amounts funded.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Astera Labs (ALAB.US) Q3 earnings and guidance exceed expectations; Scorpio rises to become the top revenue-generating product line
Astera Labs (ALAB.US) released its Q3 2026 financial report after the US stock market closed on November 3.
Surged after hours! Arista Networks (ANET.US) achieved record revenue and profit growth in Q3, with Q4 performance guidance exceeding expectations
Arista Networks released its financial results for the third quarter of 2026 ending September 30.
The US strengthens the dollar on midterm election day, rising Treasury yields provide support, and the US-Iran situation may dominate future market trends.
The US dollar strengthened on Tuesday during the US midterm elections, supported by rising US Treasury yields and robust economic data.
Crypto prices
More
